The Biologics Prescribers Collaborative applauds the Centers for Medicare and Medicaid Services (CMS) on yesterday’s announcement to reverse its policy on coding and payment for biosimilars under Medicare Part B. This gives each biosimilar of a given reference product a unique reimbursement code. This new policy reflects the fundamental science of biologics therapies, allows physicians greater ability to make prescribing decisions based on medical need, and better promotes optimal patient benefit. We look forward to continuing to work with CMS on policies surrounding biosimilars, and all biologics, as more become available in the future.
Stay Informed View the latest newsletter
To receive regular newsletters and periodic alerts from the BPC, enter your email address in the form below: